Carbonyl reductase 1/2/3 Antibody (E-5): sc-377174

Carbonyl reductase 1/2/3 Antibody (E-5) is a mouse monoclonal IgG1 kappa light chain antibody that detects Carbonyl reductase 1/2/3 (CBR1/2/3) of mouse and rat origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-CBR1/2/3 antibody (E-5) is available as a non-conjugated format. CBR1 and CBR3 proteins function as key components of the short-chain dehydrogenase/reductase family, primarily metabolizing various carbonyl compounds produced during lipid peroxidation. CBR1/2/3 proteins localize in the cytosol, catalyzing NADPH-dependent reduction of carbonyls to corresponding alcohols - a process essential for detoxifying harmful metabolites and regulating cellular redox states. Proper CBR1/2/3 enzyme function maintains metabolic homeostasis by metabolizing endogenous compounds and influencing drug pharmacokinetics. Genetic variations in CBR1/2/3 genes can cause individual differences in drug metabolism, impacting personalized medicine approaches. CBR1/2/3 protein defects have been associated with various conditions, including cancer and diabetes, underscoring their significance in normal physiology and disease states.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Carbonyl reductase 1/2/3 Antibody (E-5) References:

1. Cloning and bacterial expression of monomeric short-chain dehydrogenase/reductase (carbonyl reductase) from CHO-K1 cells.  |  Terada, T., et al. 2000. Eur J Biochem. 267: 6849-57. PMID: 11082196
2. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.  |  Olson, LE., et al. 2003. Cancer Res. 63: 6602-6. PMID: 14583452
3. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).  |  Lakhman, SS., et al. 2005. Drug Metab Dispos. 33: 254-7. PMID: 15537833
4. Fine mapping of a region on chromosome 21q21.11-q22.3 showing linkage to type 1 diabetes.  |  Bergholdt, R., et al. 2005. J Med Genet. 42: 17-25. PMID: 15635070
5. An unbiased cell morphology-based screen for new, biologically active small molecules.  |  Tanaka, M., et al. 2005. PLoS Biol. 3: e128. PMID: 15799708
6. Decreased expression of the human carbonyl reductase 2 gene HCR2 in hepatocellular carcinoma.  |  Liu, S., et al. 2006. Cell Mol Biol Lett. 11: 230-41. PMID: 16847567
7. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology.  |  Oppermann, U. 2007. Annu Rev Pharmacol Toxicol. 47: 293-322. PMID: 17009925
8. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.  |  Gonzalez-Covarrubias, V., et al. 2007. Drug Metab Dispos. 35: 973-80. PMID: 17344335
9. Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor.  |  Lakhman, SS., et al. 2007. Mol Pharmacol. 72: 734-43. PMID: 17569794
10. Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis.  |  Chang, YC., et al. 2012. J Mol Med (Berl). 90: 847-58. PMID: 22527884
11. Bergapten attenuates microglia-mediated neuroinflammation and ischemic brain injury by targeting Kv1.3 and Carbonyl reductase 1.  |  Gao, S., et al. 2022. Eur J Pharmacol. 933: 175242. PMID: 36058290
12. Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2.  |  Watanabe, K., et al. 1998. Genomics. 52: 95-100. PMID: 9740676

The preferred Carbonyl reductase 1 antibody is Carbonyl reductase 1 Antibody (B-11): sc-390554.